tirzepatide ban update WADA just added (mounjaro) to the 2026 Monitoring Program The FDA is proposing a

Evidence on PsA remains limited, with only one open-label clinical study available to date

Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling

The data stack that accompanied this policy revision was exceptional by any measure: Phase 3 results for five separate drug programs the oral GLP-1 orforglipron, the triple-hormone-receptor agonist retatrutide, Novo Nordisk's CagriSema combination, the dual agonist survodutide, and the PCSK9 inhibitor evolocumab were presented at the meeting and in several cases simultaneously published in peer-reviewed journals

Step 2: Scroll to Add-On Items Bundles are listed in the Add-On Items section below the main weekly meals

Injection site issues Local reactions at injection sites occasionally cause concern

2019;doi:10.1097/WNO.0000000000000870